ascopubs.org

Diffusing capacity for carbon monoxide (DLCO) change and outcome in advanced non-small cell lung cancer (aNSCLC) treated with immune checkpoint inhibitors (ICIs).

Effect of branched-chain amino acid metabolic interactions between HIBADH+ tumor cells and BCAT1+ macrophages on immunotherapy response in advanced NSCLC. Baseline DLCO 1.04 (0.99-1.1);p=0.1 1.04 ...
Nature

Diffusing capacity impairment is prevalent in long-term lymphoma survivors after high-dose therapy with autologous stem cell transplantation

You have full access to this article via your institution. The reduction in the patients’ diffusing capacity was marked, and for women and men, respectively, DLCO was 6.09 and 8.56 mmol/kPa/min ...